Media coverage
2
Media coverage
Title MindMed Q3 Earnings: Big Improvement, Kicks Off Sleep & Cognitive Study With Dose Low-Dose LSD Degree of recognition International Media name/outlet Benzinga Media type Online Country/Territory United States Date 16/11/21 Description MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a biotech company developing psychedelic-inspired therapies, announced its financial results ... As part of the study conducted by Dr. Kim Kuypers of Maastricht University, researchers will use digital measurement devices and software to measure the effects of microdoses of LSD on neuroplasticity markers ... Producer/Author Jelena Martinovic URL https://www.benzinga.com/general/biotech/21/11/24126855/mindmed-q3-earnings-big-improvement-kicks-off-sleep-cognitive-study-with-dose-low-dose-lsd Persons Kim Kuypers Title MindMed Q3 Earnings: Big Improvement, Kicks Off Sleep & Cognitive Study With Dose Low-Dose LSD Degree of recognition International Media name/outlet Markets Insider- Business Insider Media type Online Country/Territory United States Date 16/11/21 Description MindMed (NASDAQ:MNMD) (NEO: MMED) (DE: MMQ), a biotech company developing psychedelic-inspired therapies, announced its financial results ... .As part of the study conducted by Dr. Kim Kuypers of Maastricht University, researchers will use digital measurement devices and software to measure the effects of microdoses of LSD on ... Producer/Author Jelena Martinovic URL https://markets.businessinsider.com/news/stocks/mindmed-q3-earnings-big-improvement-kicks-off-sleep-cognitive-study-with-dose-low-dose-lsd-1030981643 Persons Kim Kuypers
Keywords
- BDNF plasma levels
- LSD on neuroplasticity
- MindMed's shares
- board directors
- cash
- cognitive performance
- development
- effects of daytime
- financial results
- individuals to access levels